Managing the Rising Costs and High Drug Expenditures in Critical Care Pharmacy Practice
详细信息 查看全文
- 作者：Alexander H. Flannery ; Komal Pandya ; Melanie E. Laine ; Philip J. Almeter and Jeremy D. Flynn
- 刊名：Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：37
- 期：1
- 页码：54-64
- 全文大小：84K
- ISSN：1875-9114
文摘
Pharmaceutical costs for patients in the intensive care unit (ICU) constitute a large portion of hospital drug budgets. Unfortunately, prices for medications commonly used in the ICU are on the rise for a variety of reasons. In particular, the U.S. Food and Drug Administration's Unapproved Drugs Initiative, generic manufacturers cornering the marketplace, drug shortages, and regulatory device changes are major drivers of pharmaceutical price escalation affecting costs in the ICU. Furthermore, traditional high acquisition cost items still pose challenges to controlling costs. To offer strategies to mitigate the rising costs of pharmaceuticals in the ICU setting, we searched the PubMed/Medline and International Pharmaceutical Abstracts databases and other related sources to identify published cost-saving protocols concerning specific medications that are affected by rising prices or have traditional high acquisition costs. In the absence of specific protocols, we offer possible cost-saving initiatives based on published literature regarding specific agents or based on our own diverse set of experiences. Finally, we review suggested clinical and operational activities at an institutional level to address these rising drug costs in the ICU setting.